Literature DB >> 18005225

CD69 upregulation on T cells as an in vitro marker for delayed-type drug hypersensitivity.

A Beeler1, L Zaccaria, T Kawabata, B O Gerber, W J Pichler.   

Abstract

BACKGROUND: T cells play a key role in delayed-type drug hypersensitivity reactions. Their reactivity can be assessed by their proliferation in response to the drug in the lymphocyte transformation test (LTT). However, the LTT imposes limitations in terms of practicability, and an alternative method that is easier to implement than the LTT would be desirable.
METHODS: Four months to 12 years after acute drug hypersensitivity reactions, CD69 upregulation on T cells of 15 patients and five healthy controls was analyzed by flow cytometry.
RESULTS: All 15 LTT-positive patients showed a significant increase of CD69 expression on T cells after 48 h of drug-stimulation exclusively with the drugs incriminated in drug-hypersensitivities. A stimulation index of 2 as cut-off value allowed discrimination between nonreactive and reactive T cells in LTT and CD69 upregulation. T cells (0.5-3%) showed CD69 up-regulation. The reactive cell population consisted of a minority of truly drug reactive T cells secreting cytokines and a higher number of bystander T cells activated by IL-2 and possibly other cytokines.
CONCLUSIONS: CD69 upregulation was observed after 2 days in all patients with a positive LTT after 6 days, thus appearing to be a promising tool to identify drug-reactive T cells in the peripheral blood of patients with drug-hypersensitivity reactions.

Entities:  

Mesh:

Substances:

Year:  2007        PMID: 18005225     DOI: 10.1111/j.1398-9995.2007.01516.x

Source DB:  PubMed          Journal:  Allergy        ISSN: 0105-4538            Impact factor:   13.146


  25 in total

Review 1.  T-cell recognition of chemicals, protein allergens and drugs: towards the development of in vitro assays.

Authors:  Stefan F Martin; Philipp R Esser; Sonja Schmucker; Lisa Dietz; Dean J Naisbitt; B Kevin Park; Marc Vocanson; Jean-Francois Nicolas; Monika Keller; Werner J Pichler; Matthias Peiser; Andreas Luch; Reinhard Wanner; Enrico Maggi; Andrea Cavani; Thomas Rustemeyer; Anne Richter; Hermann-Josef Thierse; Federica Sallusto
Journal:  Cell Mol Life Sci       Date:  2010-08-18       Impact factor: 9.261

2.  Vemurafenib acts as an aryl hydrocarbon receptor antagonist: Implications for inflammatory cutaneous adverse events.

Authors:  Heike C Hawerkamp; Andreas Kislat; Peter A Gerber; Marius Pollet; Katharina M Rolfes; Anatoly A Soshilov; Michael S Denison; Afaque A Momin; Stefan T Arold; Angeliki Datsi; Stephan A Braun; Péter Oláh; Mario E Lacouture; Jean Krutmann; Thomas Haarmann-Stemmann; Bernhard Homey; Stephan Meller
Journal:  Allergy       Date:  2019-09-03       Impact factor: 13.146

Review 3.  In vitro testing for diagnosis of idiosyncratic adverse drug reactions: Implications for pathophysiology.

Authors:  Abdelbaset A Elzagallaai; Michael J Rieder
Journal:  Br J Clin Pharmacol       Date:  2015-06-01       Impact factor: 4.335

Review 4.  [Diagnostics of drug hypersensitivity reactions].

Authors:  C Möbs; W Pfützner
Journal:  Hautarzt       Date:  2017-01       Impact factor: 0.751

Review 5.  Recent advances in the understanding of severe cutaneous adverse reactions.

Authors:  N R Adler; A K Aung; E N Ergen; J Trubiano; M S Y Goh; E J Phillips
Journal:  Br J Dermatol       Date:  2017-09-29       Impact factor: 9.302

Review 6.  In vitro testing for the diagnosis of anticonvulsant hypersensitivity syndrome: a systematic review.

Authors:  Abdelbaset A Elzagallaai; Sandra R Knowles; Michael J Rieder; John R Bend; Neil H Shear; Gideon Koren
Journal:  Mol Diagn Ther       Date:  2009       Impact factor: 4.074

Review 7.  Severe Delayed Cutaneous and Systemic Reactions to Drugs: A Global Perspective on the Science and Art of Current Practice.

Authors:  Jonathan Grant Peter; Rannakoe Lehloenya; Sipho Dlamini; Kimberly Risma; Katie D White; Katherine C Konvinse; Elizabeth J Phillips
Journal:  J Allergy Clin Immunol Pract       Date:  2017 May - Jun

8.  Delabeling Delayed Drug Hypersensitivity: How Far Can You Safely Go?

Authors:  Rannakoe J Lehloenya; Jonny G Peter; Ana Copascu; Jason A Trubiano; Elizabeth J Phillips
Journal:  J Allergy Clin Immunol Pract       Date:  2020-10

Review 9.  Drug-induced interstitial lung disease: mechanisms and best diagnostic approaches.

Authors:  Osamu Matsuno
Journal:  Respir Res       Date:  2012-05-31

10.  Vancomycin hypersensitivity diagnosed by lymphocyte blast transformation.

Authors:  Nguyen P Tran; Jeremy Katcher; Erin Rohman; Mary Francis Hall; Christie F Michael; Isao Miyairi; D Betty Lew
Journal:  Case Rep Pediatr       Date:  2011-11-24
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.